| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.8 | 5.3 |
| Gross profit | 7.7 | 3.9 |
| Profit before tax | -7.7 | -7.9 |
| Net income | -7.7 | -8.0 |
| EPS (diluted, $ a share) | $-0.21 | $-0.26 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +85.9% |
|---|---|
| Gross margin | 78.1% |
| Operating margin | -79.6% |
10-Q filed with the SEC, NASDAQ: PROF. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Profound Medical Corp.: key numbers
- Share price
- $7.34Close, Nov 16
- Market cap
- $269M
- Shares outstanding
- 36.63MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Profound Medical Corp.
All →Profound Medical Leadership Change
Profound Medical Corp. announced a leadership transition where Richard R. Fabian will succeed Arun Menawat as President and CEO effective January 15, 2027, with Dr. Menawat becoming Executive Chairman. Additionally, Jason Mills was appointed to the Board of Directors following the resignation of Cynthia Lavoie.
Profound Medical Investor Presentation
Profound Medical announced that its management team, including President Richard Fabian, CEO Arun Menawat, and CFO Matthew Sobczyk, will participate in the Stifel 2026 Healthcare Conference in New York City. Mr. Fabian is scheduled to deliver a formal presentation on November 12, 2026, and the team will conduct one-on-one meetings with institutional investors.
Profound Medical Financial Results
Profound Medical reported Q3 2026 revenue of $9.8 million, an 86% year-over-year increase, driven by strong capital equipment sales and recurring revenue. The company achieved a 78% gross margin and significantly reduced its operating cash use by 56% sequentially. Additionally, the company announced a leadership transition with Richard Fabian appointed as CEO effective January 2027.
- Term
- Q3 2026
“Revenue increased 86% year-over-year, gross margin reached 78%, and operating cash use declined substantially from the second quarter. These results, together with our commercial pipeline, support our strong full-year outlook. Our priority is to convert growing physician interest, broader payer coverage and clinical evidence into system placements and recurring procedure revenue.”
Arun Menawat, Profound’s Chief Executive Officer and Chairman
“Our new Cook Medical agreement adds a key U.S. distribution channel, complementing our own sales team’s continued focus on selling TULSA-PRO for existing 1.5T and 3.0T MRI systems outside the agreement’s scope, while preserving our direct relationships for disposables and service. With experienced leadership in place and continued investment in product efficiency, we are positioning Profound to scale toward profitable growth.”
Arun Menawat, Profound’s Chief Executive Officer and Chairman
Profound Medical Partnership with Cook Medical Holdings LLC
Profound Medical entered into a supply and distribution agreement with Cook Medical to appoint them as a non-exclusive distributor of the TULSA-PRO system in the U.S. The partnership integrates TULSA-PRO into Cook's Copernicus program for intraoperative MRI suites, expanding Profound's sales channels while retaining direct recurring revenue from disposables and service.
- Counterparty
- Cook Medical Holdings LLC
- Term
- 5 years
Profound Medical Business Update
Profound Medical announced that Emmy-Award winning host Montel Williams will join its 'Let’s Huddle' patient education webinar on November 5, 2026. The initiative focuses on prostate care advocacy and education, highlighting the company's TULSA Procedure as a treatment option.
Profound Medical Clinical Trial Data
Profound Medical announced the presentation of five abstracts at the 15th Interventional MRI Symposium regarding its TULSA-PRO system. The data included real-world validation from the CARE Registry and Mayo Clinic, as well as results from the CAPTAIN randomized controlled trial showing superior preservation of erectile function compared to robotic radical prostatectomy.
- Counterparty
- Mayo Clinic